This infographic uses data from strategy consultancy L.E.K. Consulting to examine consolidation levels within the aesthetic sector across the top three European economies: the UK, France and Germany.
UK cosmetic surgery company Transform Healthcare has gone through quite a journey in the past 15 years. In an interview with HBI, Dr. Sayani Sainudeen, Transform's new CEO, explained how the company is moving increasingly into holistic weight loss services, covering a broad range of treatments, from new injectable weight loss drugs, to surgery, to talking therapy.
HBI’s annual conference took place last week. Almost 600 attendees — comprising CXOs of healthcare providers, investors, suppliers and advisors — travelled from 40 different countries to London for the event. Over the course of three days of roundtables, workshops and panel discussions, they explored the big issues the sector faces, and the opportunities available to the private sector in helping to solve them.
At last year’s conference Hedley Goldberg, Managing Director at multinational investment bank Rothschild, predicted healthcare M&A activity would begin picking up again in Q4 2023 or Q1 2024. But we’re now halfway through 2024 and there are still very few deals above €500m taking place. Goldberg is confident, however, that we have now passed through the bottom of the cycle.
Pan-European Dutch aesthetics chain Faceland is taking advantage of the ample consolidation opportunities in Europe’s rapidly growing aesthetics sector by buying Juneco, Italy’s largest aesthetics chain. This marks Faceland’s first foray into the Italian market and will help the group achieve its plan to grow to over 50 clinics across its five European markets by the end of 2024.
German Health Minister Karl Lauterbach’s intention to ban investors from owning outpatient facilities appears to no longer have any realistic chance of being passed. Investors and advisors are consequently gearing up for a flurry of deals in H2 from pent-up demand.
Gulf Islamic Investments (GII) has acquired an equity stake worth SR600m ($160m) in Abeer Medical Company, a large affordable healthcare provider in Saudi Arabia.
Healthcare Business International users cookies to improve the functionality, performance, and effectiveness of our communications. Detailed information on the use of cookies is provided in our Cookies Policy. By continuing to use this site, or by clicking "I agree" you consent to the use of cookies.OkCookies Policy
